Article
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.
Blood - 23 Apr 2026
Sekrecki Michal, Sekrecka Agata, Lattupally Rohan R, Le Kenny, Jin Xiaokang, Mozes Chen, Dwyer Brendan G, Zhuang Zhe, Romero Bryan A, Pineda Jose M B, Cao Xunhong, Nguyen Linh, Chen Vicky, Zhou Crystal M, Wallace Jared A, Tanaka Kailee, Tiwari Charu, Gabel Austin, Kim Won Jun, Stanley Robert F, Benbarche Salima, Thind Jaspreet, Muruganandham Abhinaya, Zhang Tian Yi, Greenberg Peter L, Gotlib Jason R, Mannis Gabriel, Shomali William E, Salmasi Giselle, Kuo Calvin, Shanafelt Tait, Singh Irtisha, Inoue Daichi, Hansen Finn K, Gray Nathanael S, van Rechem Capucine, Fakhri Bita, Zhang Xiaoyu, Lu Sydney X
Abstract excerpt
ABSTRACT: Oncogenic mutations of SF3B1 are common in myeloid cancers, chronic lymphocytic leukemia (CLL), and select solid tumors. Their mechanistic basis for promoting oncogenesis has been investigated in detail, with the stereotyped missplicing of messenger RNA (mRNA) protein coding sequences most intensively studied. These changes, in genes such as MAP3K7, BRD9, and ABCB7, typically lead to loss of function,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.